EP2847175A4 - Compositions et méthodes inhibant l'activité de l'anhydrase carbonique - Google Patents

Compositions et méthodes inhibant l'activité de l'anhydrase carbonique

Info

Publication number
EP2847175A4
EP2847175A4 EP13787577.9A EP13787577A EP2847175A4 EP 2847175 A4 EP2847175 A4 EP 2847175A4 EP 13787577 A EP13787577 A EP 13787577A EP 2847175 A4 EP2847175 A4 EP 2847175A4
Authority
EP
European Patent Office
Prior art keywords
suppression
compositions
methods
carbonic anhydrase
anhydrase activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13787577.9A
Other languages
German (de)
English (en)
Other versions
EP2847175A1 (fr
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellix Bio Pvt Ltd
Original Assignee
Cellix Bio Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Pvt Ltd filed Critical Cellix Bio Pvt Ltd
Publication of EP2847175A1 publication Critical patent/EP2847175A1/fr
Publication of EP2847175A4 publication Critical patent/EP2847175A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
EP13787577.9A 2012-05-08 2013-02-03 Compositions et méthodes inhibant l'activité de l'anhydrase carbonique Withdrawn EP2847175A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1810CH2012 2012-05-08
PCT/IB2013/050899 WO2013167994A1 (fr) 2012-05-08 2013-02-03 Compositions et méthodes inhibant l'activité de l'anhydrase carbonique

Publications (2)

Publication Number Publication Date
EP2847175A1 EP2847175A1 (fr) 2015-03-18
EP2847175A4 true EP2847175A4 (fr) 2016-04-20

Family

ID=54193691

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13787577.9A Withdrawn EP2847175A4 (fr) 2012-05-08 2013-02-03 Compositions et méthodes inhibant l'activité de l'anhydrase carbonique

Country Status (7)

Country Link
EP (1) EP2847175A4 (fr)
JP (1) JP2015520748A (fr)
CN (1) CN104364241A (fr)
AU (1) AU2013257715B2 (fr)
CA (1) CA2872978A1 (fr)
SG (1) SG11201407317SA (fr)
WO (1) WO2013167994A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379589A (zh) * 2012-05-07 2015-02-25 塞利克斯比奥私人有限公司 抗血小板药剂的前药
CA2873018A1 (fr) * 2012-07-03 2014-01-09 Cellixbio Private Limited Compositions et methodes de traitement de la douleur moderee a aigue
CA3151947A1 (fr) * 2014-02-03 2015-08-06 Eidgenoessische Technische Hochschule Zuerich Conjugues de medicament a faible poids moleculaire servant a la liaison a l'anhydrase ix carbonique
WO2018211474A1 (fr) 2017-05-19 2018-11-22 Trudell Medical International Dispositif à pression expiratoire positive
CN108969521A (zh) * 2017-05-31 2018-12-11 邱正廸 乙酰唑胺治疗脑出血的用途
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0014642A2 (fr) * 1979-02-02 1980-08-20 Merck & Co. Inc. Compositions ophtalmiques comprenant des combinaisons d'inhibiteurs d'anhydrase carbonique et de S-(-)-1-(tert-butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yl)-oxy-2-propanol pour application topique dans le traitement d'hypertension intraoculaire
WO1992005786A1 (fr) * 1990-09-28 1992-04-16 Merck & Co., Inc. Combinaisons d'ibuprofene-diuretique
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US20010002404A1 (en) * 1996-05-22 2001-05-31 Webb Nigel L. Fatty acid-pharmaceutical agent conjugates
WO2011163594A2 (fr) * 2010-06-24 2011-12-29 Alkermes, Inc. Promédicaments de composés nh-acides : dérivés esters, carbonates, carbamates et phosphonates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2554816A (en) * 1950-04-04 1951-05-29 American Cyanamid Co Heterocyclic sulfonamides and methods of preparation thereof
US4134792A (en) * 1976-12-06 1979-01-16 Miles Laboratories, Inc. Specific binding assay with an enzyme modulator as a labeling substance
US5157044A (en) * 1983-02-04 1992-10-20 University Of Iowa Research Foundation Analogs of carbonic anhydrase inhibitors and their use as topical IOP inhibitors
US5104887A (en) * 1983-02-04 1992-04-14 University Of Iowa Research Foundation Topical ophthalmic imino substituted 2-imino-3-methyl-delta4-1,3,4-thiadiazoline-5-sulfonamides carbonic anhydrase inhibitors
US5242937A (en) * 1990-03-19 1993-09-07 Research Corporation Technologies, Inc. Topically active ocular thiadiazole sulfonamide carbonic anhydrase inhibitors
GB0821537D0 (en) * 2008-11-25 2008-12-31 Union Life Sciences Ltd Therapeutic target
WO2010147666A1 (fr) * 2009-06-19 2010-12-23 Memorial Sloan-Kettering Cancer Center Composés utiles en tant que modulateurs de l'anhydrase carbonique et leurs utilisations
CN101921245B (zh) * 2010-08-30 2012-04-18 中国人民解放军军事医学科学院卫生学环境医学研究所 抑制碳酸酐酶ⅱ的磺胺类化合物及合成方法与用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0014642A2 (fr) * 1979-02-02 1980-08-20 Merck & Co. Inc. Compositions ophtalmiques comprenant des combinaisons d'inhibiteurs d'anhydrase carbonique et de S-(-)-1-(tert-butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yl)-oxy-2-propanol pour application topique dans le traitement d'hypertension intraoculaire
WO1992005786A1 (fr) * 1990-09-28 1992-04-16 Merck & Co., Inc. Combinaisons d'ibuprofene-diuretique
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US20010002404A1 (en) * 1996-05-22 2001-05-31 Webb Nigel L. Fatty acid-pharmaceutical agent conjugates
WO2011163594A2 (fr) * 2010-06-24 2011-12-29 Alkermes, Inc. Promédicaments de composés nh-acides : dérivés esters, carbonates, carbamates et phosphonates

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AGRAWAL V K ET AL: "QSAR study on topically acting sulfonamides incorporating GABA moieties: A molecular connectivity approach", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 16, no. 7, 1 April 2006 (2006-04-01), pages 2044 - 2051, XP027966394, ISSN: 0960-894X, [retrieved on 20060401] *
ILIES M ET AL: "Carbonic anhydrase inhibitors: sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 8, no. 8, 1 August 2000 (2000-08-01), pages 2145 - 2155, XP027414362, ISSN: 0968-0896, [retrieved on 20000801] *
JENNIFFER I. ARENAS-GARCÍA ET AL: "Modification of the Supramolecular Hydrogen-Bonding Patterns of Acetazolamide in the Presence of Different Cocrystal Formers: 3:1, 2:1, 1:1, and 1:2 Cocrystals from Screening with the Structural Isomers of Hydroxybenzoic Acids, Aminobenzoic Acids, Hydroxybenzamides, Aminobenzamides, Nicotinic Acids,", CRYSTAL GROWTH & DESIGN., vol. 12rge, no. 2, 1 February 2012 (2012-02-01), US, pages 811 - 824, XP055255392, ISSN: 1528-7483, DOI: 10.1021/cg201140g *
LOFTSSON T ET AL: "The effect of water-soluble polymers on the aqueous solubility and complexing abilities of beta-cyclodextrin", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 163, no. 1-2, 1 January 1998 (1998-01-01), pages 115 - 121, XP003003295, ISSN: 0378-5173, DOI: 10.1016/S0378-5173(97)00371-2 *
See also references of WO2013167994A1 *

Also Published As

Publication number Publication date
CN104364241A (zh) 2015-02-18
AU2013257715B2 (en) 2016-05-05
SG11201407317SA (en) 2014-12-30
EP2847175A1 (fr) 2015-03-18
WO2013167994A1 (fr) 2013-11-14
CA2872978A1 (fr) 2013-11-14
JP2015520748A (ja) 2015-07-23
AU2013257715A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
HK1251246A1 (zh) 用於使組合物脫硫的方法和組合物
ZA201508059B (en) Compositions and methods of use of phorbol esters
EP2836224A4 (fr) Compositions de microbiota et leurs procédés associés
IL233476B (en) Carbamate compounds and methods for their production and use
AP3965A (en) Anthelminitic compounds and compositions and method of using thereof
EP2776567A4 (fr) Compositions et méthodes pour le traitement d'infections par cytomégalovirus
EP2675471A4 (fr) Compositions liées à la sérumalbumine humaine et procédés d'utilisation
HK1193837A1 (zh) 聚脲組合物及其使用方法
SG10202009963PA (en) Melanin modification compositions and methods of use
EP2836218A4 (fr) Compositions prébiotiques et leurs procédés d'utilisation
EP2834322A4 (fr) Compositions de biocharbon et leurs procédés d'utilisation
EP2672820A4 (fr) Composés mannosides et leurs procédés d'utilisation
EP2771030A4 (fr) Compositions et méthodes de traitement de protéinopathies
EP2847175A4 (fr) Compositions et méthodes inhibant l'activité de l'anhydrase carbonique
EP2748190A4 (fr) Compositions wnt et utilisations thérapeutiques desdites compositions
EP2667889A4 (fr) Compositions de wnt et procédés d'utilisation de celles-ci
IL227924B (en) Preparations and methods of use for determining a4he
EP2753337A4 (fr) Compositions comprenant des bêta-glucanes et leurs procédés d'utilisation
EP2906041A4 (fr) Compositions et procédés d'utilisation d'un composé de lutte contre l'inappétence
EP2755668A4 (fr) Compositions dérivées de hyr1 et méthodes de traitement les utilisant
EP2809337A4 (fr) Effecteurs de la ss-arrestine et compositions et procédés d'utilisation de ceux-ci
EP2859071A4 (fr) Compositions chimiques et leurs procédés d'utilisation
HK1212998A1 (zh) 組合物及其使用方法
EP2841164A4 (fr) Compositions appropriées au derme et méthodes d'utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 285/135 20060101AFI20151006BHEP

Ipc: A61P 27/06 20060101ALI20151006BHEP

Ipc: A61K 31/433 20060101ALI20151006BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160322

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 285/135 20060101AFI20160316BHEP

Ipc: A61K 31/433 20060101ALI20160316BHEP

Ipc: A61P 27/06 20060101ALI20160316BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20160511